THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA
Authors:
Open Access
- 3 January 2011
- journal article
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 3 (1) , e2011031
Abstract
Secondary myelodisplasia (MDS) and acute myeloide leukaemia (AML) are frequent long term complications in Chronic Lymphocytic Leukemia (CLL) and Waldesntrom Macroglobulinemia (WM) patients. Although disease-related immune-suppression plays a crucial role in leukemogenesis there is great concern that therapy may further increase the risk of developing these devastating complications. Nucleoside analogs (NA) and alkilator agents are considered appropriate agents in the treatment of both CLL and WM patients. Prolonged immunosuppression related to nucleoside analogs therapy and the incorporation of these agents or their metabolites into DNA, with potentially mutagenic action, leads to speculation that their therapeutic use might be responsible for an increased incidence of second cancer especially when combined with other DNA damaging agents like alkylators. In this review the published studies considering the occurrence of secondary MDS and AML in CLL and WM patients are reported and the potential role of chemotherapeutic agents in leukemogenesis is discussed.Keywords
This publication has 53 references indexed in Scilit:
- Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemiaCancer, 2011
- Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712Journal of Clinical Oncology, 2011
- Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter StudyJournal of Clinical Oncology, 2010
- Epigenetic changes in therapy-related MDS/AMLChemico-Biological Interactions, 2010
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Fludarabine in the treatment of chronic lymphocytic leukemia: a reviewTherapeutics and Clinical Risk Management, 2009
- Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemiaLeukemia, 2006
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patientsLeukemia, 2005
- Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 casesBritish Journal of Haematology, 2001